Comparing the current results to its competitors, Taro Pharmaceutical Industries Ltd reported Revenue increase in the 4 quarter 2023 by 2.07 % year on year, while most of its competitors have experienced contraction in revenues by -2.08 %, achieved in the same quarter.
Taro Pharmaceutical Industries Ltd Net Income in the 4 quarter 2023 fell year on year by -56.33%, while most of its competitors have experienced a contraction in net income by -31.8 %.
With modest revenue growth of 2.07 % within Overall company, Taro Pharmaceutical Industries Ltd managed to improve its market share within this segment to approximately 0.89 %. << More on TARO Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Taro Pharmaceutical Industries Ltd
Abbott Laboratories Share Performance
+25.09%
This Quarter
Abbott Laboratories
Profile
Abbott Laboratories operates as a diversified healthcare company with a focus on developing and manufacturing a wide range of health-related products, including pharmaceuticals, medical devices, nutritional products, and diagnostic technologies. Their business model emphasizes innovation and quality, aiming to address the diverse needs of patients and healthcare providers across various sectors globally. By leveraging their expertise and extensive portfolio, Abbott strives to enhance patient outcomes and improve the overall quality of life.
Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.
Puma Biotechnology Inc operates as a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for the treatment of cancer. Their business model revolves around identifying promising preclinical and clinical drug candidates, conducting rigorous research and development, and seeking regulatory approval for their products. Puma Biotechnology Inc strives to effectively market and distribute their approved therapeutics to provide patients with potentially life-saving treatment options.
Perrigo Company Plc is a leading global healthcare supplier that focuses on providing affordable, high-quality over-the-counter (OTC) healthcare and wellness products. The company operates through its own worldwide distribution network, manufacturing a wide range of products and medications. By leveraging its extensive portfolio and efficient supply chain, Perrigo aims to enhance the well-being of consumers by making quality healthcare products more accessible.
Dr. Reddy's Laboratories Ltd is a multinational pharmaceutical company that operates on a vertically integrated business model. They focus on the development, manufacturing, and marketing of a wide range of generic and branded pharmaceutical products. By leveraging their strong research and development capabilities and global presence, they aim to provide affordable and high-quality healthcare solutions to patients worldwide.
Sources:
Taro Pharmaceutical Industries Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Taro Pharmaceutical Industries Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
